In a collaboration announced this week, Pfizer and Korea's Samsung Medical Center will employ gene signatures in the development drug/diagnostic combination products for the personalized treatment of liver cancer.

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.